Now showing items 1-20 of 102

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03)
      Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11)
      Background The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ...
    • A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. 

      Smyth, EC; Nyamundanda, G; Cunningham, D; Fontana, E; Ragulan, C; Tan, IB; Lin, SJ; Wotherspoon, A; Nankivell, M; Fassan, M; Lampis, A; Hahne, JC; Davies, AR; Lagergren, J; Gossage, JA; Maisey, N; Green, M; Zylstra, JL; Allum, WH; Langley, RE; Tan, P; Valeri, N; Sadanandam, A (2018-12)
      Background Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk ...
    • A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. 

      Ingles Garces, AH; Ang, JE; Ameratunga, M; Chénard-Poirier, M; Dolling, D; Diamantis, N; Seeramreddi, S; Sundar, R; de Bono, J; Lopez, J; Banerji, U (2018-11)
      Background The incidence and clinical significance of electrolyte abnormalities (EAs) in phase I clinical trials are unknown. The objective of this study is to evaluate the incidence and severity of EAs, graded according ...
    • Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG. 

      Grünwald, V; Litière, S; Young, R; Messiou, C; Lia, M; Wardelmann, E; van der Graaf, W; Gronchi, A; Judson, I; EORTC STBSG (2016-09)
      Background Anthracycline-based chemotherapy remains the mainstay of first-line treatment in metastatic or advanced soft-tissue sarcoma (STS). Age, performance status, tumour histology and tumour grade are recognised ...
    • Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. 

      Demetri, GD; Schöffski, P; Grignani, G; Blay, J-Y; Maki, RG; Van Tine, BA; Alcindor, T; Jones, RL; D'Adamo, DR; Guo, M; Chawla, S (2017-10)
      Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overall survival (OS) for the eribulin arm, with a manageable ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
    • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. 

      Eggermont, AMM; Blank, CU; Mandala, M; Long, GV; Atkinson, V; Dalle, S; Haydon, A; Lichinitser, M; Khattak, A; Carlino, MS; Sandhu, S; Larkin, J; Puig, S; Ascierto, PA; Rutkowski, P; Schadendorf, D; Koornstra, R; Hernandez-Aya, L; Maio, M; van den Eertwegh, AJM; Grob, J-J; Gutzmer, R; Jamal, R; Lorigan, P; Ibrahim, N; Marreaud, S; van Akkooi, ACJ; Suciu, S; Robert, C
      BACKGROUND:The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate ...
    • Age as an independent prognostic factor for survival of localised synovial sarcoma patients. 

      Vlenterie, M; Ho, VKY; Kaal, SEJ; Vlenterie, R; Haas, R; van der Graaf, WTA (2015-12)
      Background We performed a retrospective nationwide study to explore age as a prognostic factor in synovial sarcoma patients.Methods Data on 613 synovial sarcoma patients were obtained from the Netherlands Cancer Registry. ...
    • An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. 

      Maley, CC; Koelble, K; Natrajan, R; Aktipis, A; Yuan, Y (2015-09-22)
      Introduction Abundance of immune cells has been shown to have prognostic and predictive significance in many tumor types. Beyond abundance, the spatial organization of immune cells in relation to cancer cells may also have ...
    • An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. 

      Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; O'Sullivan, JM; Vogelzang, NJ; Bruland, Ø; Kobina, S; Wilhelm, S; Xu, L; Shan, M; Kattan, MW; Parker, C (2017-05)
      Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, ...
    • Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer. 

      Nawaz, S; Trahearn, NA; Heindl, A; Banerjee, S; Maley, CC; Sottoriva, A; Yuan, Y (2019-10-21)
      BACKGROUND:Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ...
    • Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. 

      Conteduca, V; Wetterskog, D; Sharabiani, MTA; Grande, E; Fernandez-Perez, MP; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, MJ; Climent, MA; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, MI; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G (2017-07)
      Background There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma ...
    • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. 

      Frezza, AM; Jones, RL; Lo Vullo, S; Asano, N; Lucibello, F; Ben-Ami, E; Ratan, R; Teterycz, P; Boye, K; Brahmi, M; Palmerini, E; Fedenko, A; Vincenzi, B; Brunello, A; Desar, IME; Benjamin, RS; Blay, JY; Broto, JM; Casali, PG; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Mir, O; Rutkowski, P; Wagner, AJ; Anurova, O; Collini, P; Dei Tos, AP; Flucke, U; Hornick, JL; Lobmaier, I; Philippe, T; Picci, P; Ranchere, D; Renne, SL; Sbaraglia, M; Thway, K; Wagrodzki, M; Wang, W-L; Yoshida, A; Mariani, L; Kawai, A; Stacchiotti, S (2018-09-13)
      Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the ...
    • Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. 

      Latimer, NR; Abrams, KR; Lambert, PC; Morden, JP; Crowther, MJ (2018-03)
      When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation ...
    • Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. 

      de Morrée, ES; Vogelzang, NJ; Petrylak, DP; Budnik, N; Wiechno, PJ; Sternberg, CN; Doner, K; Bellmunt, J; Burke, JM; Ochoa de Olza, M; Choudhury, A; Gschwend, JE; Kopyltsov, E; Flechon, A; van As, N; Houede, N; Barton, D; Fandi, A; Jungnelius, U; Li, S; Li, JS; de Wit, R (2017-01)
      Importance The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it is beneficial for patients to continue ...
    • Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. 

      Fuchs, CS; Tabernero, J; Tomášek, J; Chau, I; Melichar, B; Safran, H; Tehfe, MA; Filip, D; Topuzov, E; Schlittler, L; Udrea, AA; Campbell, W; Brincat, S; Emig, M; Melemed, SA; Hozak, RR; Ferry, D; Caldwell, CW; Ajani, JA (2016-10)
      Background Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell ...
    • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 

      Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; Lee, J-S; Hochmair, MJ; Li, JY-C; Chang, G-C; Lee, KH; Gridelli, C; Delmonte, A; Garcia Campelo, R; Kim, D-W; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018-11)
      Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of ...
    • Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. 

      de Wit, R; de Bono, J; Sternberg, CN; Fizazi, K; Tombal, B; Wülfing, C; Kramer, G; Eymard, J-C; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdóttir, Á; Theodore, C; Feyerabend, S; Helissey, C; Ozatilgan, A; Geffriaud-Ricouard, C; Castellano, D; CARD Investigators (2019-12)
      Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously ...